Predictive model of chemotherapy-related toxicity in elderly Chinese cancer patients
暂无分享,去创建一个
[1] R. de Bree,et al. The association between skeletal muscle measures and chemotherapy‐induced toxicity in non‐small cell lung cancer patients , 2022, Journal of cachexia, sarcopenia and muscle.
[2] Wei-Ming Huang,et al. Pulmonary vascular volume is associated with DLCO and fibrotic score in idiopathic pulmonary fibrosis: an observational study , 2021, BMC Medical Imaging.
[3] Sudeep Gupta,et al. Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study , 2021, BMJ Open.
[4] A. Pan,et al. Epidemiology and determinants of obesity in China. , 2021, The lancet. Diabetes & endocrinology.
[5] H. Grabsch,et al. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer , 2021, JAMA oncology.
[6] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[7] K. Shiu,et al. Challenges in the treatment of gastric cancer in the older patient. , 2020, Cancer treatment reviews.
[8] C. Gross,et al. Associations between nutritional factors and chemotherapy toxicity in older adults with solid tumors , 2020, Cancer.
[9] Jun Zhang,et al. Prospective comparison of the value of CRASH and CARG toxicity scores in predicting chemotherapy toxicity in geriatric oncology , 2019, Oncology letters.
[10] F. Lordick,et al. The performance of three oncogeriatric screening tools - G8, optimised G8 and CARG - in predicting chemotherapy-related toxicity in older patients with cancer. A prospective clinical study. , 2019, Journal of geriatric oncology.
[11] N. Kassebaum,et al. Measuring population ageing: an analysis of the Global Burden of Disease Study 2017 , 2019, The Lancet. Public health.
[12] M. Reni,et al. Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives. , 2019, Cancer treatment reviews.
[13] J. Feliu,et al. Can we avoid the toxicity of chemotherapy in elderly cancer patients? , 2018, Critical reviews in oncology/hematology.
[14] Myung Ah Lee,et al. Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study , 2018, British Journal of Cancer.
[15] P. Valent,et al. Anemia at older age: etiologies, clinical implications, and management. , 2018, Blood.
[16] F. Bozzetti,et al. Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] T. Hsu,et al. Comprehensive Geriatric Assessment in the Older Adult with Cancer: A Review. , 2017, European urology focus.
[18] C. Gross,et al. Predictors of chemotherapy dose reduction at first cycle in patients age 65 years and older with solid tumors. , 2015, Journal of geriatric oncology.
[19] S. Yusuf,et al. The burden of disease in older people and implications for health policy and practice , 2015, The Lancet.
[20] H. Cohen,et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] H. Chun,et al. Chemotherapy for Advanced Gastric Cancer: Review and Update of Current Practices , 2013, Gut and liver.
[22] G. Lyman,et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score , 2012, Cancer.
[23] F.–C. Zhang,et al. Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity , 2012, Journal of clinical pharmacy and therapeutics.
[24] J. Sabate,et al. Nutritional Status Affects Treatment Tolerability and Survival in Metastatic Colorectal Cancer Patients: Results of an AGEO Prospective Multicenter Study , 2012, Oncology.
[25] Joseph O. Deasy,et al. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting , 2011 .
[26] Supriya G Mohile,et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] B. Goh,et al. Comparison of the pharmacokinetics and pharmacodynamics of S‐1 between Caucasian and East Asian patients , 2011, Cancer science.
[28] W. Cheung,et al. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] O. Arrieta,et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study , 2010, BMC Cancer.
[30] A. Brunello,et al. Dose adjustment and supportive care before and during treatment. , 2009, Cancer treatment reviews.
[31] E. Van Cutsem,et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Lesley Seymour,et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] O. Gajic,et al. Low baseline serum creatinine concentration predicts mortality in critically ill patients independent of body mass index* , 2007, Critical care medicine.
[34] D. Berry,et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] T. Hickish,et al. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. , 2006, European journal of cancer.
[36] J. Ajani,et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] S. Wade,et al. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. , 2004, The American journal of medicine.
[38] R. Fortinsky,et al. Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. , 2000, JAMA.
[39] M. Highley,et al. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. , 1999, Anti-cancer drugs.
[40] J. Concato,et al. The Risk of Determining Risk with Multivariable Models , 1993, Annals of Internal Medicine.
[41] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[42] W. Youden,et al. Index for rating diagnostic tests , 1950, Cancer.